Department of Breast Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, 261 Huansha Road, Hangzhou, 310006, China.
School of Life Science, Huzhou University, 759 Erhuan East Road, Huzhou, 313000, Zhejiang, China.
J Nat Med. 2021 Jan;75(1):156-166. doi: 10.1007/s11418-020-01469-8. Epub 2020 Nov 20.
Astragaloside IV (ASV), which has several pharmacological abilities, shows potential therapeutic effects on certain cancers by regulating the expression of long noncoding RNA (lncRNA). However, the anticancer role that ASV plays by regulating lncRNAs in breast cancer remains unknown. In this study, we first demonstrated that the lncRNA of TRHDE antisense RNA 1 (TRHDE-AS1) was downregulated in breast cancer tissues and cells. Low TRHDE-AS1 expression is associated with poor outcomes in patients with breast cancer and potentially contributes to the aggressive tumor biology of breast cancer. Furthermore, ASV significantly increased TRHDE-AS1 expression in a dose- and time-dependent manner in breast cancer cells. By upregulating TRHDE-AS1, ASV repressed breast cancer cell growth and metastasis both in vitro and in vivo. Taken together, our data indicated that TRHDE-AS1 participates in the anticancer role of ASV in breast cancer, which provides evidence for the application of ASV for breast cancer therapy.
黄芪甲苷 (ASV) 具有多种药理作用，通过调节长链非编码 RNA (lncRNA) 的表达显示出对某些癌症的潜在治疗效果。然而，ASV 通过调节 lncRNA 在乳腺癌中的抗癌作用尚不清楚。在这项研究中，我们首先证明了 TRHDE 反义 RNA 1 (TRHDE-AS1) 的 lncRNA 在乳腺癌组织和细胞中下调。低 TRHDE-AS1 表达与乳腺癌患者的不良预后相关，并可能有助于乳腺癌的侵袭性肿瘤生物学。此外，ASV 以剂量和时间依赖的方式显著增加乳腺癌细胞中 TRHDE-AS1 的表达。通过上调 TRHDE-AS1，ASV 抑制了乳腺癌细胞在体外和体内的生长和转移。综上所述，我们的数据表明 TRHDE-AS1 参与了 ASV 在乳腺癌中的抗癌作用，为 ASV 在乳腺癌治疗中的应用提供了证据。
